SLGL - ソル・ゲル・テクノロジ―ズ （Sol-Gel Technologies Ltd.）

While the concept of high-risk speculation seems particularly dangerous at this juncture, gamblers may nevertheless want to consider the merits of targeting potentially lucrative biotech stocks that could be the next big thing. These lesser-known enterprises may not command worldwide attention at the moment. Nevertheless, they could yield tremendous profitability if they come through. Another factor that benefits high-risk, high-reward biotech stocks centers on the underlying sector’s permanent relevance. No matter what’s going on with the economy or which bank happens to be failing, scientists will continue marching forward. Chronic diseases don’t wait for economic cycles to pass by and neither does the medical innovation sector. Indeed, when the equities sector crumbled in 2022, the broader healthcare sector generally provided a solid performance . While individual biotechs present volatility risks, the search for viable therapeutics represents a perpetual endeavor. On that note, below are the biotech stocks to add to your portfolio.

Sol-Gel Technologies press release (SLGL): FY GAAP EPS of -$0.65 misses by $0.15.Revenue of $3.88M (-87.6% Y/Y) misses by $1.8M.As of December 31,…

Sol-Gel Technologies press release (SLGL): Q3 GAAP EPS of -$0.15 misses by $0.08.Revenue of $0.3M (-96.6% Y/Y) misses by $3.15M.As of September 30, 2022, Sol-Gel had $25.5 million…

NESS ZIONA, Israel, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded and generic topical drug products for the treatment of skin diseases, announced today financial results for the third quarter ended September 30, 2022 and provided a corporate update.

U.S. stocks traded mostly higher midway through trading, with the Dow Jones surging more than 300 points on Monday. The Dow traded up 1.03% to 31,402.66 while the NASDAQ rose 0.07% to 10,867.39. The S&P 500 also rose, gaining, 0.66% to 3,777.37. Also check this: Market Volatility Decreases As Dow Jumps More Than 700 Points Leading and Lagging Sectors Health care shares climbed 1.7% on Monday. Leading the sector was strength from Vaxcyte, Inc. (NASDAQ: PCVX ) and Sol-Gel Technologies Ltd. (NASDAQ: SLGL ). In trading on Monday, consumer discretionary shares fell by 0.8%. Top Headline The S&P Global manufacturing PMI dropped to 49.9 in October from 52 in September, down from market estimates of 51. US services PMI fell to 46.6 in October from 49.3 in the prior month. Equities Trading UP Vaxcyte, Inc. (NASDAQ: PCVX ) shares shot up 70% to $35.03 after the company announced positive topline results from the Phase 1/2 clinical proof-of-concept study evaluating the safety, tolerability and immunogenicity of VAX-24.

Sol-Gel Technologies press release (SLGL): Q3 GAAP EPS of -$0.15 misses by $0.08.Revenue of $0.3M (-96.6% Y/Y) misses by $3.15M.As of September 30, 2022, Sol-Gel had $25.5 million…

NESS ZIONA, Israel, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded and generic topical drug products for the treatment of skin diseases, announced today financial results for the third quarter ended September 30, 2022 and provided a corporate update.

U.S. stocks traded mostly higher midway through trading, with the Dow Jones surging more than 300 points on Monday. The Dow traded up 1.03% to 31,402.66 while the NASDAQ rose 0.07% to 10,867.39. The S&P 500 also rose, gaining, 0.66% to 3,777.37. Also check this: Market Volatility Decreases As Dow Jumps More Than 700 Points Leading and Lagging Sectors Health care shares climbed 1.7% on Monday. Leading the sector was strength from Vaxcyte, Inc. (NASDAQ: PCVX ) and Sol-Gel Technologies Ltd. (NASDAQ: SLGL ). In trading on Monday, consumer discretionary shares fell by 0.8%. Top Headline The S&P Global manufacturing PMI dropped to 49.9 in October from 52 in September, down from market estimates of 51. US services PMI fell to 46.6 in October from 49.3 in the prior month. Equities Trading UP Vaxcyte, Inc. (NASDAQ: PCVX ) shares shot up 70% to $35.03 after the company announced positive topline results from the Phase 1/2 clinical proof-of-concept study evaluating the safety, tolerability and immunogenicity of VAX-24.

Sol-Gel Technologies press release (SLGL): Q2 GAAP EPS of $0.01 beats by $0.11.Revenue of $3.5M (+288.9% Y/Y) misses by $1.11M.

NESS ZIONA, Israel, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded and generic topical drug products for the treatment of skin diseases, announced today financial results for the second quarter ended June 30, 2022 and provided a corporate update.

U.S. stocks traded mostly higher midway through trading, with the Dow Jones surging more than 300 points on Monday. The Dow traded up 1.03% to 31,402.66 while the NASDAQ rose 0.07% to 10,867.39. The S&P 500 also rose, gaining, 0.66% to 3,777.37. Also check this: Market Volatility Decreases As Dow Jumps More Than 700 Points Leading and Lagging Sectors Health care shares climbed 1.7% on Monday. Leading the sector was strength from Vaxcyte, Inc. (NASDAQ: PCVX ) and Sol-Gel Technologies Ltd. (NASDAQ: SLGL ). In trading on Monday, consumer discretionary shares fell by 0.8%. Top Headline The S&P Global manufacturing PMI dropped to 49.9 in October from 52 in September, down from market estimates of 51. US services PMI fell to 46.6 in October from 49.3 in the prior month. Equities Trading UP Vaxcyte, Inc. (NASDAQ: PCVX ) shares shot up 70% to $35.03 after the company announced positive topline results from the Phase 1/2 clinical proof-of-concept study evaluating the safety, tolerability and immunogenicity of VAX-24.

Sol-Gel Technologies press release (SLGL): Q2 GAAP EPS of $0.01 beats by $0.11.Revenue of $3.5M (+288.9% Y/Y) misses by $1.11M.

NESS ZIONA, Israel, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded and generic topical drug products for the treatment of skin diseases, announced today financial results for the second quarter ended June 30, 2022 and provided a corporate update.

Gainers United Maritime Corporation (NASDAQ: USEA ) shares jumped 180.9% to $6.19. United Maritime, on Tuesday, announced acquisition of four oil tankers and filed for stock offering on Wednesday. Cemtrex, Inc. (NASDAQ: CETX ) gained 52.8% to $0.4759 after gaining over 5% on Thursday. Nymox Pharmaceutical Corporation (NASDAQ: NYMX ) rose 43.5% to $0.3101 after declining over 36% on Thursday. NYMOX received deficiency letter from NASDAQ. ITHAX Acquisition Corp. (NASDAQ: ITHX ) surged 34.7% to $13.41. NexImmune, Inc. (NASDAQ: NEXI ) jumped 29.9% to $1.9099 after the company received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for its first cellular therapy product candidate NEXI-003 addressing solid tumors.. ToughBuilt Industries, Inc. (NASDAQ: TBLT ) gained 21% to $2.8899 after gaining 10% on Thursday. ToughBuilt Industries recently announced its Q2 gross sales through Amazon were $3.56 million, representing a 20% year-over-year increase. Greenbrook TMS Inc. (NASDAQ: GBNH ) rose 19.7% to $1.6999.

NESS ZIONA, Israel, June 01, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded and generic topical drug products for the treatment of skin diseases, today announced that Chief Executive Officer, Alon Seri-Levy, will present a corporate update at the 2022 Jefferies Global Healthcare Conference to be held June 8 -10, 2022 in-person, in New York, NY.